Antimicrobial Resistance (AMR) in India: Beyond Antibiotic Overuse

Context

A recent ICMR study has found that infections caused by carbapenem-resistant Gram-negative bacteria are associated with higher death rates and higher antibiotic costs than infections caused by bacteria that remain sensitive to these drugs. The study also highlights that India’s AMR problem is driven not only by antibiotic misuse but also by delayed diagnosis, hospital transmission and poor infection control.

What is Antimicrobial Resistance (AMR)?

1. Antimicrobial Resistance (AMR) occurs when microorganisms such as bacteria, viruses, fungi or parasites develop the ability to survive medicines that were earlier effective against them.
2. In bacterial infections, this means that commonly used antibiotics stop working effectively, making infections harder to treat.
3. AMR can develop naturally, but unnecessary or excessive use of antibiotics speeds up the process by allowing resistant bacteria to survive and multiply.

Gram-Negative Bacteria and Carbapenems

1. Gram-negative bacteria have a thin cell wall along with an additional outer membrane. They appear pink or red under Gram staining.
2. They can cause serious infections of the lungs, urinary tract, wounds and bloodstream.
3. Important hospital-associated Gram-negative bacteria include: coli, Klebsiella pneumonia, Acinetobacter baumannii and Pseudomonas aeruginosa.
4. Carbapenems are strong antibiotics commonly used when treating severe bacterial infections, especially when other medicines may not work.
5. When bacteria become carbapenem-resistant, treatment becomes much more difficult because doctors are left with very limited effective antibiotic options.

Findings of the ICMR Study

1. The study was carried out through ICMR’s AMR surveillance network across 20 tertiary-care hospitals between April 2022 and April 2025. Patients infected with carbapenem-resistant strains had a higher risk of death across all four major Gram-negative bacteria studied.
2. Their relative risk of death was around 16–1.43 times higher than patients infected with drug-sensitive strains. More than 61% of the Gram-negative infections recorded in the study were resistant to carbapenems.
3. However, resistance should not be considered the only reason for death. Outcomes are also influenced by how seriously ill the patient is, how quickly treatment begins, whether the source of infection is controlled and individual patient factors.
4. Thus, carbapenem resistance is an important indicator of additional health risk, rather than an independent explanation for every death.

Why is AMR Increasing?

The study shows that AMR results from several interconnected factors:

1. Excessive antibiotic use creates pressure that favours resistant bacteria.
2. Delayed diagnosis may result in inappropriate treatment and allow infections to become more severe.
3. Spread within healthcare facilities can transmit resistant bacteria from one patient to another.
4. Invasive medical devices, recent surgeries and gaps in infection-control practices can increase the risk of infection.

Economic Burden

1. Resistant infections also make treatment more expensive because stronger or newer antibiotics may be required.
2. In the ICMR study, the researchers calculated only the cost of antibiotics available through the Jan Aushadhi scheme. Even this limited calculation showed that antibiotic expenses for resistant infections were around 1–2 times higher.
3. The actual financial burden is likely much greater because the study did not include ICU expenses, hospital bed charges, diagnostic tests, supportive treatment, consultation costs, etc.

Newer Antibiotics: A Cautious Signal

1. The study observed better outcomes in some resistant coli and Klebsiella pneumoniae infections among patients treated with ceftazidime-avibactam, including certain bloodstream infections.
2. However, this does not establish that the drug is universally superior to other treatments.
3. The study was observational, so factors such as disease severity, timing of treatment and specific resistance mechanisms could not be completely accounted for.
4. Therefore, its findings represent real-world evidence from India, rather than a definitive ranking of antibiotics.
5. This highlights the importance of rapid and accurate diagnosis so that doctors can select the right medicine instead of automatically shifting to newer and broader antibiotics.

Prevention is as Important as Treatment

1. More than 85% of bloodstream infections in the study were linked to healthcare settings.
2. This indicates that controlling AMR requires hospitals to strengthen infection prevention, rather than relying mainly on increasingly powerful antibiotics.
3. Important measures include:
   1. Better hand hygiene
   2. Preventing infections linked to medical devices
   3. Proper insertion and timely removal of invasive devices
   4. Regular environmental cleaning
   5. Stronger infection prevention during surgeries
   6. Monitoring healthcare-associated infections
4. Antimicrobial stewardship is equally important. Doctors should use antibiotics only when required, select the most appropriate medicine, and avoid unnecessarily prolonged treatment.

Way Forward

1. Integrated surveillance: Link laboratory data with information on patient outcomes, treatment and deaths to understand the real impact of AMR.
2. Faster diagnostics: Develop better tests that can quickly identify bacterial infections and detect resistance.
3. Stronger stewardship: Make responsible antibiotic prescribing a routine part of medical practice.
4. Better infection control: Give prevention of hospital-acquired infections equal importance to antibiotic treatment.
5. Responsible access to newer drugs: Ensure that advanced antibiotics are available to patients who genuinely need them while protecting their effectiveness through proper stewardship.

Conclusion

AMR is not simply a consequence of overusing antibiotics. The ICMR study shows that resistant infections, particularly carbapenem-resistant ones, can increase both mortality and treatment costs, while hospital transmission and weak infection-control systems can further worsen the problem.

India therefore needs a prevention-first approach: prevent infections, diagnose them early, prescribe antibiotics carefully and preserve newer medicines for situations where they are truly necessary.

FAQs

Q1. What is Antimicrobial Resistance (AMR)? 

AMR occurs when microorganisms (bacteria, viruses, fungi, parasites) survive medicines that once worked against them, making infections harder to treat.

Q2. How does AMR develop? 

It can occur naturally, but misuse or overuse of antibiotics accelerates resistance by allowing resistant strains to survive and multiply.

Q3. What are Gram‑negative bacteria and why are they important? 

They have a thin cell wall plus an outer membrane, causing serious infections (lungs, urinary tract, wounds, bloodstream). Key examples: E. coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa.

Q4. What are carbapenems and why is resistance critical? 

Carbapenems are strong antibiotics used for severe infections. Resistance leaves doctors with very limited treatment options.

Q5. What did the ICMR study find about carbapenem resistance? 

Across 20 hospitals (2022–25), carbapenem‑resistant infections had 1.16–1.43 times higher death risk; 61% of Gram‑negative infections were resistant.

Q6. Is resistance the only cause of death in these cases? 

No. Outcomes also depend on illness severity, speed of treatment, infection source control, and patient factors.

Q7. Why is AMR increasing in India? 

Due to antibiotic misuse, delayed diagnosis, hospital transmission, invasive devices, surgeries, and weak infection‑control practices.

Q8. What is the economic burden of AMR? 

Resistant infections raise antibiotic costs 1.1–2 times (Jan Aushadhi data). Actual burden is higher when ICU, diagnostics, procedures, and supportive care are included.

Q9. Are newer antibiotics a solution? 

Drugs like ceftazidime‑avibactam showed better outcomes in some resistant infections, but evidence is observational. Rapid diagnosis is key to choosing the right drug.

Q10. How can AMR be prevented? 

Through better hand hygiene, infection‑control in hospitals, careful use of invasive devices, antimicrobial stewardship, faster diagnostics, and responsible access to newer drugs.